• Product NameRelugolix
• Brief DescriptionInhibitors
• Purification98.64%
• Biological ActivityRelugolix is a novel, non-peptide, orally active gonadotropin-releasing hormone (GnRH) antagonist with IC50 of 0.33 nM in the presence of 40% fetal bovine serum, TAK-385 possesses higher affinity and potent antagonistic activity compared with TAK-013.
• Target NameGNRH Receptor inhibitor
• CAS No. 737789-87-6
• Calculated MW 623.63
• Formulation C29H27F2N7O5S
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cancer/ Nervous system
  SMILES:CN(C)CC1=C(SC2=C1C(=O)N(C(=O)N2CC3=C(C=CC=C3F)F)C4=NN=C(C=C4)OC)C5=CC=C(C=C5)NC(=O)NOC
  Pathways:GPCR/G Protein
  Receptor:GNRHR
  Boling pt:
  Melting pt:
  Solubility:Soluble in DMSO
  Appearance:Powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. MacLean DB et al. J Clin Endocrinol Metab. 2015 Dec;100(12):4579-87.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting